NCT02444741View on ClinicalTrials.gov

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

September 17, 2015

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Malignant Solid NeoplasmMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
RADIATION

3-Dimensional Conformal Radiation Therapy

Undergo 3D-CRT

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Proton Beam Radiation Therapy

Undergo PBRT

RADIATION

Radiation Therapy

Undergo low dose radiation therapy

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter